Key Takeaways
- Phagos closes a $30 million Series A round co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter.
- Other investors include Acurio Ventures, Citizen Capital, Entrepreneurs First, Founders Capital, and Station F.
- Funding will accelerate deployment of veterinary phage therapies, AI platform development, and global expansion.
- The company achieved a regulatory first as the world’s first firm authorized to market personalized phage-based veterinary drugs.
- Phagos aims to tackle antimicrobial resistance and extend its solutions from animal health to human medicine.
Phagos Secures $30 Million to Advance Phage Therapy for Animal Health
Phagos, a biotechnology company pioneering phage therapy as an alternative to antibiotics, has announced a $30 million Series A funding round to accelerate its international growth and technology development. The round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter, with participation from Acurio Ventures, Citizen Capital, Entrepreneurs First, Founders Capital, and Station F.
The new funding will enable Phagos to scale its veterinary phage therapy solutions, expand research and development capabilities, and strengthen its presence in Europe, Asia, and the Americas.
Addressing Antimicrobial Resistance Through AI and Microbiology
Founded in 2021 by Alexandros Pantalis and Dr. Adèle James, Phagos has developed a proprietary platform that integrates microbiology and artificial intelligence to design precision phage therapies—natural viral treatments that target and eliminate specific bacteria.
The company’s approach addresses the escalating challenge of antimicrobial resistance (AMR), which causes millions of deaths annually and threatens both human and animal health. In livestock, one in three antibiotics is now ineffective, underscoring the need for alternative solutions.
Phagos’ AI-driven platform analyzes complete bacterial and phage genomes to predict effective interactions, enabling the design of targeted, scalable, and personalized therapies. The company’s first applications focus on animal health—specifically bacterial pathogens such as Salmonella and E. coli—with future plans to extend to human medicine.
Regulatory Milestone and Global Expansion
Phagos recently became the first company globally authorized to market personalized phage-based veterinary treatments, marking a major regulatory milestone for the sector. The company has also filed patents for its AI technology and initiated pilot deployments with industry partners across multiple continents.
With the new capital, Phagos will scale up manufacturing and field deployment of its veterinary treatments, expand its scientific team, and accelerate the development of the next generation of its AI discovery platform. Currently, 90% of its workforce is composed of scientific and technical specialists supporting research and commercialization efforts.
Investor Perspectives on Phagos’ Growth and Impact
“We are convinced that phage therapy can transform the history of medicine just as antibiotics did in the last century,” said Alexandros Pantalis and Dr. Adèle James, co-founders of Phagos. “This funding allows us to accelerate our mission and make phage therapy accessible, effective, and scalable against bacterial resistance—first in animal health, and ultimately in human health.”
Anne-Valérie Bach, Managing Director at CapAgro, noted: “Antimicrobial resistance is a defining challenge for global food systems. With its regulatory approval and AI-powered discovery platform, Phagos is leading the way in deploying actionable, sustainable alternatives to antibiotics.”
Rob Kniaz, Founder and Emeritus Partner at Hoxton Ventures, added: “Phagos’ pioneering platform offers a high-efficiency alternative to antibiotics, with the potential to reshape how bacterial infections are treated and to establish a new standard in both animal and human health.”
Outlook
With its Series A funding secured, Phagos plans to further its mission of combating bacterial diseases through phage therapy, combining scientific innovation with regulatory and commercial readiness. The company’s goal is to make phage-based treatments a scalable, mainstream solution to bacterial infections—supporting healthier, more sustainable food systems and global health outcomes.
